



This is a repository copy of *Do overly complex reporting guidelines remove the focus from good clinical trials?*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/177647/>

Version: Accepted Version

Article:

Howick, J., Webster, R. orcid.org/0000-0002-5136-1098, Knottnerus, J.A. et al. (1 more author) (2021) Do overly complex reporting guidelines remove the focus from good clinical trials? *British Medical Journal*, 374. n1793. ISSN 0959-8138

<https://doi.org/10.1136/bmj.n1793>

This article has been accepted for publication in *British Medical Journal*, 2021 following peer review, and the Version of Record can be accessed online at <https://doi.org/10.1136/bmj.n1793>. © Authors (or their employer(s)) 2021. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) <https://creativecommons.org/licenses/by-nc/4.0/>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Head to Head

Do overly complex reporting guidelines remove the focus from good clinical trials?

Jeremy Howick,¹ director, Oxford Empathy Programme; Rebecca Webster,² lecturer in psychology; J André Knottnerus,³ emeritus professor of general practice; David Moher, director⁴ and professor⁵

¹Faculty of Philosophy, University of Oxford, UK

²Department of Psychology, University of Sheffield, UK

³Maastricht University, Netherlands

⁴Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute University of Ottawa, Canada

⁵School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Canada

Correspondence to: J A Knottnerus andre.knottnerus@maastrichtuniversity.nl, D Moher dmoher@ohri.ca

The ever increasing emphasis on complex reporting guidelines is getting in the way of designing and conducting good clinical trials, say **Jeremy Howick, Rebecca Webster, and J André Knottnerus**. But **David Moher** argues that, while following the guidelines can be frustrating, such complexity remains necessary and is improving research, not impeding it

Yes—Jeremy Howick, Rebecca Webster, and J André Knottnerus

In 1996 a group of medical journal editors, clinical trialists, epidemiologists, and methodologists met in Chicago to develop a checklist to help researchers report the results of their clinical trials completely and transparently.¹ The result was the Consolidated Standards of Reporting Trials (Consort), which has aimed to improve reporting of randomised controlled trials (RCTs) ever since.

The original 1996 statement included a half page guide embedded in a three page explanatory document.² The updated 2010 Consort statement includes 25 items embedded in a 28 page paper, as well as a separate explanatory document. That's just the basic version. There are versions of Consort for trials of herbal treatments, orthodontic treatments, feasibility, and at least 25 other subtypes.³ And that's just Consort; many other reporting guidelines have been developed since 1996.

Multiple guidelines are often required for a single study, each with a host of supplementary documents. Identifying, understanding, and implementing these guidelines takes time and effort.

This would be justified if these efforts all improved study quality—or better still, patient outcomes. Such evidence is absent.

The fact is that guideline developers measure their success by checking to see how well researchers adhere to the guidance.⁴ Such efforts often reveal that the guidelines are barely used.⁵ Worse, checking whether guidelines are used doesn't tell us whether the guidelines (in their current form) are useful for improving research in the first place.

Perverse incentives

In addition, since successful (or successfully followed) guidelines lead to multiple publications and are widely cited, perverse incentives are likely to proliferate the problem of too many guidelines. Further, the proliferation of complex reporting guidelines can remove the focus away from designing and conducting good trials or from detecting poor trial design. This is supported by the following reasons.

First, generating, identifying, studying, and referencing the complex web of guidelines is a time consuming process that diverts scarce resources from designing clinically sound hypotheses and conducting good research. Second, compliance with reporting guidelines creates a veneer of detailed sound reporting that can distract from fundamental problems in a trial.

Trials of questionable value have continued to thrive despite Consort. In 2015, for example, researchers conducted a placebo controlled trial looking at the efficacy of a three month formulation of paliperidone palmitate in patients with schizophrenia,⁶ finding that the treatment was superior to placebo. The trial was well reported in terms of adherence to the reporting guidance. However, previously published systematic reviews⁷ had already established the efficacy of antipsychotics for reducing relapse in patients with schizophrenia. The authors did not explain why a placebo controlled trial of a new intervention was conducted instead of a trial of a new intervention versus a proven therapy.⁸

Another well-reported trial suggested that the diabetes drug rosiglitazone effectively lowered blood glucose (a surrogate outcome). It was subsequently found that the drug increased cardiovascular events (the outcome relevant to patients).⁹

In another example, three of four well reported industry sponsored trials evaluating newer antihypertensive drugs used atenolol as the comparator, although a low dose thiazide diuretic had been found to be superior.¹⁰

These examples show how a well reported trial with inappropriate comparators or outcomes is wasteful and may lead to the adoption of useless or even harmful interventions that lack benefits. They also show that the complex web of reporting guidelines the researchers meticulously followed failed to catch this, improve the trial design, or prevent such trials from happening in the first place.

The simpler the better

Counterintuitively, simpler guidelines may be more rigorous.¹¹ For example, Green and Mehr introduced a simple clinical guideline to determine whether a patient with chest pain should be sent to a coronary care unit.¹² This resulted in better sensitivity and specificity than a complex, 50 question instrument.

Moher argues that “. . . such as with pharmaceuticals, we should be more cautious about recommending the use of reporting guidelines without evidence of effectiveness.”¹³ We agree. In our view, the effectiveness of the current state of affairs—namely, many complex guidelines—must be formally compared with the use of vastly simplified, single guidelines.

The proliferation of increasingly complex guidelines needs to be tamed in the same way as the problem of too much medicine: with evidence based evaluation.

No—David Moher

Researchers have always struggled to report their randomised trials (RCTs)[OK?] completely and transparently.¹⁴ This is why experts involved in the process, from journal editors to clinicians and methodologists, met as early as 1993 to find a solution. The resulting guidelines^{15 16} include the 1994 publication of [or “a 1994 publication by”?] the Standards of Reporting Trials (Sort) group[OK?], aiming to provide prospective authors with guidance on reporting their trial design, methods, and results. They were not alone: Drummond Rennie, a deputy editor of *JAMA*,[OK?] was a member of a separate initiative called Asilomar that met about six months later with a similar remit to Sort’s. He brought both groups together, resulting in the original Consort statement in 1996.

Consort had two fundamental goals at its inception. Its longer term goal is to improve the quality of RCTs through better reporting, which admittedly remains distant.¹⁷ But its immediate goal of improving the transparency and completeness of reporting RCTs is arguably being achieved, even if the implementation is complex.

For example, reporting of allocation concealment in reports of RCTs is more complete in journals that endorse the Consort guidance than in journals that do not.⁵ The development of the Spirit standard for trial protocols in 2013 has brought further improvement in the transparency of protocols for RCTs.¹⁸ If authors have adequately described the method used for allocation concealment in their protocol, and if there has been no deviation of this during the trial, it should be easy to include this information in the final report of the completed trial.

Clear problems, not so clear solutions

Undoubtedly, since Consort's birth the number of guidelines has proliferated: there are numerous extensions to Consort, while Equator (the Enhancing the QUALity and Transparency Of health Research Network) contains a comprehensive open access library of more than 400 reporting guidelines.

Admittedly, this can be confusing for the people conducting the trials, particularly if they are required to use multiple guidance. Journals also differ in their endorsement, often not recommending that peer reviewers use reporting guidelines when peer reviewing a manuscript, and most [journals?] have not publicly indicated whether they monitor their endorsement of reporting guidelines. Some reporting guidelines have never been cited,¹⁹ suggesting a lack of use.

But while the problems are clear, I think that the solutions are more complex. Even if guidance were made simpler, the evidence underpinning reporting recommendations takes time to accumulate. When Consort was created in 1996, there was little evidence about the consequences of outcome reporting biases or spin on the results and interpretation of RCTs. We know better today, and reporting guidelines need to be updated to reflect this knowledge.

While providing evidence will always be the main justification for reporting items in clinical trials, clarity and common sense are other important reasons. Authors who report their trial design, methods, and results completely and transparently may have an easier time disseminating their message. And, without an audit of the publication of RCT results, it's very difficult to continue to improve or change their practice for the better. Feedback to authors would help, but I am unaware of any journal or publisher that provides this type of audit and feedback on its website or to individual researchers. [OK?]

Incentives

Just making guidelines simpler would not necessarily increase the number of people using them or improve the quality of reporting. A bigger problem is that authors are not incentivised or

rewarded for using reporting guidelines in the first place. What if researchers were assessed as to whether they used a guideline when reporting their research, rather than the ubiquitous “publish or perish”?²⁰ The metadata are available to enable automated compilation of this information. Researchers could include this information in their curriculum vitae.

It’s not that the problems of complexity are not acknowledged or that no efforts are under way to fix them. Journal editors have repeatedly urged the use of technology to help authors adhere to reporting guidelines. Authors can use Penelope (an Equator wizard)[OK?], and members of the newly merged Spirit and Consort executive are working to incorporate some of the key extensions into a single checklist.

While I understand why busy clinicians call for simpler guidance, I question the belief that this would improve the quality of clinical trial reporting. Conducting trials, even pragmatic real world trials, is complex and takes time. Shouldn’t we have a similar philosophy for reporting them?

Biographies

Jeremy Howick is director of the Oxford Empathy Programme and a senior researcher in the Faculty of Philosophy at the University of Oxford. He has published three books including *The Philosophy of Evidence-Based Medicine*.

Rebecca Webster is a lecturer in psychology at the University of Sheffield. She has held previous research positions at King’s College, London and at the University of Oxford, where she was involved in the development of a reporting guideline for placebo controlled trials.

J André Knottnerus is an epidemiologist, emeritus professor of general practice at Maastricht University, and member of the Royal Netherlands Academy of Sciences. He was scientific director of the Netherlands School of Primary Care Research, president of the Health Council of the Netherlands, and co-editor in chief of the *Journal of Clinical Epidemiology*.

David Moher directs the Centre for Journalology and the[OK?] Clinical Epidemiology Program at the Ottawa Hospital Research Institute. He has published on many topics including reporting guidelines. He developed the Consort and Prisma statements and has been involved in the development of other reporting guidelines. He is a fellow of the Canadian Academy of Health Sciences and the Royal Society of Canada.

Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: JH, RW, and JAK have no competing interests to declare; DM developed the Consort and Prisma statements and has been involved in the development of other reporting guidelines.

Provenance and peer review: Commissioned, externally peer reviewed.

1 Consort. How Consort began. <http://www.consort-statement.org/about-consort/history>.

2 Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the Consort statement. *JAMA* 1996;276:637-9. doi:10.1001/jama.1996.03540080059030.

- 3 Equator Network. Enhancing the QUALity and Transparency Of health Research. <https://www.equator-network.org>.
- 4 Moher D, Jones A, Lepage L, for the Consort Group. Use of the Consort statement and quality of reports of randomized trials: a comparative before-and-after evaluation. *JAMA* 2001;285:1992-5. doi:10.1001/jama.285.15.1992.
- 5 Turner L, Shamseer L, Altman DG, et al. Does use of the Consort statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. *Syst Rev* 2012;1:60. <https://doi.org/10.1186/2046-4053-1-60>.
- 6 Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. *JAMA Psychiatry* 2015;72:830-9. doi:10.1001/jamapsychiatry.2015.0241.
- 7 Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. *Am J Psychiatry* 2003;160:1209-22. doi:10.1176/appi.ajp.160.7.1209.
- 8 Knottnerus JA, Tugwell P. Inadequate comparators produce misleading results—the importance of good comparison practice. *J Clin Epidemiol* 2019;110:v-vi. doi:10.1016/j.jclinepi.2019.04.010.
- 9 Heneghan, C., Goldacre, B. & Mahtani, K.R. Why clinical trial outcomes fail to translate into benefits for patients. *Trials* **18**, 122 (2017). <https://doi.org/10.1186/s13063-017-1870-2>.
- 10 Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: compelling science or commercial speech? *JAMA* 2006;295:1704-6.
- 11 Gigerenzer G, Todd PM. Simple heuristics that make us smart. Oxford University Press, 1999.
- 12 Green L, Mehr DR. What alters physicians' decisions to admit to the coronary care unit? *J Fam Pract* 1997;45:219-26.
- 13 Moher D. Reporting guidelines: doing better for readers. *BMC Med* 2018;16:233. <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-018-1226-0>.
- 14 Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. *Lancet* 2014;383:267-76. doi:10.1016/S0140-6736(13)62228-X.
- 15 Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. *JAMA* 1994;272:1926-31. Erratum in: *JAMA* 1995;273:776.
- 16 Moher D, Hopewell S, Schulz KF, et al. Consort 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869.
- 17 Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. *BMJ* 2010;340:c723. doi:10.1136/bmj.c723.
- 18 Gryaznov D, Odutayo A, von Niederhäusern B, et al. Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (Aspire) study and associated projects. *Trials* 2020;21:896. doi:10.1186/s13063-020-04808-y.
- 19 Caulley L, Cheng W, Catalá-López, et al. Citation impact was highly variable for reporting guidelines of health research: a citation analysis. *J Clin Epidemiol* 2020;127:96-104. doi:10.1016/j.jclinepi.2020.07.013.

Item: BMJ-UK; Article ID: howickmoher20210714;

Article Type: Standard article; TOC Heading: Head to Head; DOI: 10.1136/bmj.n1793

20 Rice DB, Raffoul H, Ioannidis JPA, Moher D, et al. Academic criteria for promotion and tenure in biomedical sciences faculties: cross sectional analysis of international sample of universities. *BMJ* 2020;369:m2081. doi:10.1136/bmj.m2081.